NAP1L1-MLLT10 is a rare recurrent translocation that is associated with HOXA activation and poor treatment response in T-cell acute lymphoblastic leukaemia by Bond, Jonathan et al.
NAP1L1-MLLT10 is a rare recurrent translocation that
is associated with HOXA activation and poor treatment
response in T-cell acute lymphoblastic leukaemia
Jonathan Bond, Aurore Touzart, Agata Cieslak, Ame´lie Trinquand, Tony
Marchand, Martine Escoffre, Audrey Contet, Marc Muller, Claudine Schmitt,
Thierry Fest, et al.
To cite this version:
Jonathan Bond, Aurore Touzart, Agata Cieslak, Ame´lie Trinquand, Tony Marchand, et al..
NAP1L1-MLLT10 is a rare recurrent translocation that is associated with HOXA activation and
poor treatment response in T-cell acute lymphoblastic leukaemia. British Journal of Haema-
tology, Wiley, 2016, 174 (3), pp.470-473. <10.1111/bjh.13772>. <hal-01217983>
HAL Id: hal-01217983
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01217983
Submitted on 14 Jan 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
NAP1L1-MLLT10 is a rare recurrent 
translocation that is associated with HOXA 
activation and poor treatment response in 
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MLLT10 (previously AF10) was originally described as a fusion partner of the KMT2A 
(previously MLL) gene in acute myeloid leukaemia (AML) (Beverloo et al, 1995), and was 
subsequently found to be recurrently rearranged in both AML and T-acute lymphoblastic 
leukaemia (T-ALL) (Dreyling et al, 1998). PICALM (previously CALM) is the most frequent 
MLLT10 translocation partner in T-ALL, where it is found in 6-7% of cases (Ben Abdelali 
et al, 2013). The list of MLLT10 partners in T-ALL now also comprises NAP1L1 (Zhang 
et al, 2012), HNRNPH1, DDX3X (Brandimarte et al, 2013) and XPO1 (Bond et al, 2014). 
While DDX3X-MLLT10 has been estimated to occur in about 3% of adult T-ALL cases 
(Brandimarte et al, 2014), all other fusion transcripts have to date been described in single 
cases only, and their precise incidence remains to be defined. 
The NAP1L1-MLLT10 rearrangement was originally discovered by whole genome sequencing 
of leukaemic blasts from a child with early thymic precursor (ETP) ALL (Zhang et al, 2012). 
Diagnostic karyotypes of two T-ALL patients revealed similar t(10;12) translocations 
(Table 1), leading us to suspect the presence of NAP1L1-MLLT10. Expression of the 
transcript was confirmed by reverse transcription polymerase chain reaction (RT-PCR) 
(Fig 1A), and direct sequencing revealed fusion of NAP1L1 exon 14 and MLLT10 exon 4 in 
both cases (Fig 1B). 
Table 1. Clinical details of the NAP1L1-MLLT10 positive patients. HOXA9 expression was 
calculated relative to the housekeeping gene ABL1, whereby a ratio of 1 indicated equivalent 




  Patient A Patient B 
1. WBC, white blood cell; TCR, T-cell receptor; TRG, TCR gamma; MRD, minimal 
residual disease; SCT, Stem cell transplant; GVHD, Graft-versus-host disease. 
Age (years) 16 22 
Sex Male Male 
WBC count (×109/l) 25·6 297·9 
Immunophenotype 
CD34− CD1a− CD3− cCD3+ CD5+ 
CD7+ CD4weak 
CD8− CD10− TCRAB− TCRGD− 
MPO− 
CD117− CD13+ CD33+ HLA-DR+
CD34− CD1aweak CD2− CD3+ 
CD5+ CD7+ CD4+ 
CD8− CD10+ TCRGD+ CD13− 
CD33− CD117− 
CNS Infiltration No No 
Karyotype 46,XY,t(10;12)(p11;q14) 46,XY,t(10;12)(p1?2;q14) 
HOXA9/ABL1 3 1·7 
TCR status Immature, TRG rearranged TCRγδ Positive 
NOTCH1  Wild-type Mutated 
FBXW7  Mutated Wild-type 
PTEN/NRAS/KRAS  Wild-type Not performed 
MRD Positive Positive 
Clinical course 
Persistent MRD positivity (3%) 
post-induction and 
consolidation phases of treatment.
Underwent SCT 7 months post-
diagnosis. 
Remained in remission from 
leukaemia but died 2 years 




Figure 1. Characterization of the NAP1L1-MLLT10 translocation in T-ALL. (A) RT-PCR 
using primers specific for NAP1L1-MLLT10. The expected product size of 454 bp is observed 
for Patient A (Lane 2) and Patient B (Lane 1). Two other patients (Lanes 3 and 4) are 
negative. NTC, no template control. (B) Confirmation of expression of an in-frame NAP1L1-
MLLT10 fusion transcript by direct (Sanger) sequencing. Exon numbers are indicated. (C) 
Screening of 565 T-ALL patients for NAP1L1-MLLT10. PCR testing was targeted to cases 
with elevated HOXA9. The screening cut-off was based on the lowest HOXA9/ABL1 
associated with a known HOXA-activating genetic abnormality (0·5 in a PICALM-MLLT10 
patient). In order not to exclude NAP1L1-MLLT10 cases that might have lower HOXA 
expression, the testing threshold was extended to patients with HOXA9/ABL1 ≥ 0·4. Numbers 
in the relevant groups are indicated. Of the 173 HOXA High cases, 91 had known HOXA-
activating translocations, and 63 of the remaining 82 had material available for analysis. (D) 
Taqman Low-Density Array (TLDA) analysis of HOX gene transcription in NAP1L1-
MLLT10 cases. Patient (Pt) samples show specific increases in HOXA gene expression 
relative to three normal thymic (Thy) controls, while other HOX loci were not activated. 
Clinical details of the NAP1L1-MLLT10 patients are shown in Table 1. Strikingly, both were 
found to have high expression of HOXA9 by quantitative real time RT-PCR (QRT-PCR). 
Similar to the index case, Patient A had an ETP-ALL-like immunophenotype, with absence of 
CD1a, and expression of HLA-DR and the CD13 and CD33 myeloid markers (Table 1). 
Detailed characterization of T-cell receptor gene configuration revealed biallelic 
rearrangement of TRD and TRG and incomplete rearrangement of the TRB locus, conforming 
to an immature pre-β-selection immunogenotype (Asnafi et al, 2003). In contrast, Patient B 
exhibited a mature TCRγδ+ phenotype and absence of expression of myeloid markers. In 
common with the reported cases of DDX3X-MLLT10 T-ALL (Brandimarte et al, 2014), both 
cases had NOTCH1-activating mutations. 
Notably, both patients had poor initial treatment responses, with positive minimal residual 
disease (MRD). Patient B had persistent MRD positivity throughout induction and 
consolidation therapy, which necessitated allogeneic stem cell transplantation (allo-SCT) 
7 months after diagnosis. Although this resulted in molecular remission, the patient ultimately 
died of SCT-related complications 2 years later while in remission from leukaemia. The 
follow-up of Patient A is at an early stage, and latest assessment revealed significant 
persistent MRD positivity following the consolidation phase. 
We sought to determine the incidence of the NAP1L1-MLLT10 translocation in T-ALL by 
screening 565 cases, comprising 141 patients under 16 years of age and 424 adults, using a 
specific and sensitive (<1%, data not shown) QRT-PCR assay (Fig 1C). As MLLT10 
translocations are normally associated with HOXA locus activation (Brandimarte et al, 2013; 
Bond et al, 2014), we targeted the screening to 173 patients with elevated HOXA9 at 
diagnosis (‘HOXA High’ in Fig 1C). We detected no further cases of NAP1L1-MLLT10 in 
patients for whom leukaemic material was available for testing. We therefore estimate the 
incidence of the translocation in T-ALL to be 0·35% (2/565 patients), and 1·2% of patients 
with HOXA9/ABL1 >0·4 (2/173 patients). 
HOXA overexpression has not previously been described to be associated with NAP1L1-
MLLT10. In order to fully characterize HOX transcription in these cases, we performed 
Taqman Low-Density Array (TLDA) analysis of diagnostic RNA. This revealed specific 
deregulation of HOXA gene expression in both samples (Fig 1D). These results, along with 
the predicted retention of the MLLT10 octapeptide-motif leucine zipper (OM-LZ) domain in 
the fusion protein, suggest that NAP1L1-MLLT10 is likely to recruit the DOT1 Ligand 
histone methyltransferase and to activate the HOXA locus by a similar mechanism as 
PICALM-MLLT10 (Okada et al, 2005). 
It remains unclear how the activities of MLLT10 fusion partners might contribute to T-ALL 
biology. Prediction of NAP1L1 (Nucleosome assembly protein 1-like1) function is based on 
its structural resemblance to NAP1, which is thought to be involved primarily in chromatin 
modulation. NAP1 has been shown to interact directly with histone H2A-H2B dimers in vitro 
(Okuwaki et al, 2010), suggesting that NAP1L1 might alter the regulation of histone 
dynamics. It remains to be determined whether the epigenetic effects of NAP1L1 
haploinsufficiency and/or activity of a NAP1L1 fusion protein might contribute to a 
leukaemic phenotype. 
In summary, NAP1L1-MLLT10 is a rare recurrent translocation in T-ALL and we report an 
overall incidence of 0·35%. This may be an underestimation, as our QRT-PCR screening 
method may not have identified patients with novel breakpoints, and lack of diagnostic 
material precluded screening in 11% of HOXA-overexpressing patients. Reassuringly, all 
three cases of NAP1L1-MLLT10 described to date exhibited the t(10;12) translocation by 
conventional karyotyping, and none of our patient cohort had evidence of chromosome 10 or 
12 rearrangement. As with other MLLT10 fusions, NAP1L1-MLLT10 is associated with 
HOXA deregulation and poor early treatment response. Although one of our patients died of 
transplant-related complications, the prolonged leukaemia-free survival in this case suggests 
that these patients should be considered for allo-SCT in first remission, particularly in the 
event of persistent treatment resistance and/or MRD positivity. 
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